Quarterly report · Q2
7446.TEDINET S100QQHV
Period2022-10-01 → 2023-03-31
Filed2023-05-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.4bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥37.3bn | 2021-10-01 → 2022-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥19.2bn | 2021-10-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥532m | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥551m | 2021-10-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥552m | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-10-01 → 2022-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥572m | 2021-10-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥552m | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥546m | 2021-10-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥367m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥658m | 2021-10-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥372m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥373m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥388m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥17.8bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥17.5bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥16.7bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.8bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2022-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.4bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥660m | at 2021-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥185m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥886m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥984m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥288m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥92m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥83m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥46m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥186m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥102m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥407.21 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥204.9 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥728.76 | 2021-10-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥411.92 | 2021-10-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥248.5 | 2022-01-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 38.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-10-01 → 2023-03-31 | ¥101m |
| Otherother segments | revenue external | 2022-10-01 → 2023-03-31 | ¥101m |
| jpcrp040300-q2r_E02810-000Foodreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥1.7bn |
| jpcrp040300-q2r_E02810-000Foodreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥1.7bn |
| jpcrp040300-q2r_E02810-000Pharmaceutical Productsreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥9.2bn |
| jpcrp040300-q2r_E02810-000Pharmaceutical Productsreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥9.2bn |
| jpcrp040300-q2r_E02810-000Reagent For Clinical Testreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥7.5bn |
| jpcrp040300-q2r_E02810-000Reagent For Clinical Testreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥7.5bn |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥18.4bn |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥18.4bn |
| Otherother segments | revenue | 2021-10-01 → 2022-03-31 | ¥125m |
| Otherother segments | revenue external | 2021-10-01 → 2022-03-31 | ¥125m |
| jpcrp040300-q2r_E02810-000Foodreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥1.6bn |
| jpcrp040300-q2r_E02810-000Foodreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥1.6bn |
| jpcrp040300-q2r_E02810-000Pharmaceutical Productsreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥9.7bn |
| jpcrp040300-q2r_E02810-000Pharmaceutical Productsreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥9.7bn |
| jpcrp040300-q2r_E02810-000Reagent For Clinical Testreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥7.8bn |
| jpcrp040300-q2r_E02810-000Reagent For Clinical Testreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥7.8bn |
| —segment total | revenue | 2021-10-01 → 2022-03-31 | ¥19.2bn |
| —segment total | revenue external | 2021-10-01 → 2022-03-31 | ¥19.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 520
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -828000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -1133000 | JPY |
| Income taxes paid refund ope cf | Prior1YTDDuration | -124879000 | JPY |
| Income taxes paid refund ope cf | CurrentYTDDuration | -186105000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 983835000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 185485000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -12867000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -79585000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | － | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -189174000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -11347000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -23030000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | 255000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 5000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -39202000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -139202000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 139201000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 139202000 | JPY |
| Proceeds from distribution of investment in partnerships inv cf | Prior1YTDDuration | 1097000 | JPY |
| Proceeds from distribution of investment in partnerships inv cf | CurrentYTDDuration | － | JPY |
| Other net inv cf | Prior1YTDDuration | 6037000 | JPY |
| Other net inv cf | CurrentYTDDuration | -1258000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | 83173000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -288048000 | JPY |
| Increase in short term loans payable fin cf | Prior1YTDDuration | 1498000000 | JPY |
| Increase in short term loans payable fin cf | CurrentYTDDuration | 1166000000 | JPY |
| Decrease in short term loans payable fin cf | Prior1YTDDuration | -1435200000 | JPY |
| Decrease in short term loans payable fin cf | CurrentYTDDuration | -1083200000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -7140000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -7140000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -95564000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -103351000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -35340000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Other net fin cf | Prior1YTDDuration | -27101000 | JPY |
| Other net fin cf | CurrentYTDDuration | -18782000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -102346000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -46474000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 964662000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -149036000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 659982000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1268452000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 1624644000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1119415000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 690323000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 707696000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 820000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | -1738000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 57565000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 57560000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |